Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241666

SCHEMBL1241666

SCHEMBL1241666

ClCc1c(Br)cccc1Br

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.33
▸ TAAR1 Q96RJ0 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ IDO1 P14902 2/20 0.31
▸ PLCG1 P19174 1/20 0.31
▸ AHR P35869 1/20 0.31
▸ GABRA1 P14867 1/20 0.31
▸ GABRB2 P47870 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30831849 0.85 TAAR1 (0.43) ALDH1A1TAAR1CYP1A2TSHRLMNA
SCHEMBL21768197 0.85 TAAR1 (0.43) ALDH1A1TAAR1CYP1A2TSHRLMNA
SCHEMBL30831838 0.83 L3MBTL1 (0.35) L3MBTL1AHR
SCHEMBL29668673 0.83 TAAR1 (0.41) ALDH1A1TAAR1
SCHEMBL21768211 0.83 L3MBTL1 (0.35) L3MBTL1AHR
SCHEMBL6213929 0.83 ALDH1A1 (0.48) L3MBTL1ALDH1A1TAAR1CYP1A2CYP2D6
SCHEMBL3072191 0.83 TAAR1 (0.41) ALDH1A1TAAR1
SCHEMBL25368225 0.78 NOS3 (0.32) —
SCHEMBL21768190 0.78 DYRK1A (0.41) CYP1A2TSHRHSD17B10LMNA
SCHEMBL21768194 0.78 HTR2A (0.42) L3MBTL1ALDH1A1CYP1A2CYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108017522-B Preparation process of 2, 6-dibromobenzene methane sulfonyl chloride 贵州大学 2021-01-05 — — CN claimed
CN-108017522-A A kind of preparation process of 2,6- dibromos tosylate chloride 贵州大学 2018-05-11 — — CN claimed
US-4450298-A Vapor phase catalytic hydrolysis of benzal chloride or its halogen- or trifluoromethyl-substitute to form benzaldehyde or substitute CENTRAL GLASS COMPANY, LIMITED (JP) 1984-05-22 — — US claimed
CN-117820333-A KRAS G12C inhibitors 伊莱利利公司 2024-04-05 — — CN disclosed
CN-114828964-B KRAS G12C inhibitors 伊莱利利公司 2023-11-24 — — CN disclosed
US-20230339968-A1 KRAS Gl2C INHIBITORS ELI LILLY AND COMPANY 2023-10-26 — — US disclosed
US-20230339968-A1 KRAS Gl2C INHIBITORS ELI LILLY AND COMPANY 2023-10-26 — — US disclosed
US-20230339968-A1 KRAS Gl2C INHIBITORS ELI LILLY AND COMPANY 2023-10-26 — — US disclosed
US-11731984-B2 KRas G12C inhibitors ELI LILLY AND COMPANY (US) 2023-08-22 — — US disclosed
US-11731984-B2 KRas G12C inhibitors ELI LILLY AND COMPANY (US) 2023-08-22 — — US disclosed
US-11731984-B2 KRas G12C inhibitors ELI LILLY AND COMPANY (US) 2023-08-22 — — US disclosed
CN-108017522-A A kind of preparation process of 2,6- dibromos tosylate chloride 贵州大学 2018-05-11 — — CN disclosed
US-7884234-B2 N-[4-(tert-butyl)benzyl]-N-[4 -(trifluoromethoxy)biphenyl-3-yl]oxamic Acid; Inhibitors of plasminogen activator inhibitor-1 (PAI-1); thrombogenesis, fibrogenesis, accumulation of visceral fat, cell proliferation, angiogenesis INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-02-08 — — US disclosed
US-20090215899-A9 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-08-27 — — US disclosed
EP-2072498-A1 N-PHENYLOXAMIDIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-06-24 — — EP disclosed
US-20080249175-A1 N-Phenyloxamide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-10-09 — — US disclosed
CN-1651142-A Catalyst component used for ethylene oligomerization, preparing process and application thereof DAQING PETROCHEMICAL BRANCH CO (CN) 2005-08-10 — — CN disclosed
CN-1108193-C Novel catalyst for ethylene trimerization, its preparation process and application RES INST BEIJING YANSHAN PETRO (CN) 2003-05-14 — — CN disclosed
CN-1256968-A Novel catalyst for ethylene trimerization, its preparation process and application RES INST BEIJING YANSHAN PETRO (CN) 2000-06-21 — — CN disclosed
US-4450298-A Vapor phase catalytic hydrolysis of benzal chloride or its halogen- or trifluoromethyl-substitute to form benzaldehyde or substitute CENTRAL GLASS COMPANY, LIMITED (JP) 1984-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249175-A1 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 L3MBTL1 1734/4885ALDH1A1 397/4885TAAR1 2133/4885
US-20230339968-A1 KRAS Gl2C INHIBITORS KRAS, NRAS, GLS2 L3MBTL1 2522/4885ALDH1A1 1144/4885TAAR1 2999/4885
US-11731984-B2 KRas G12C inhibitors KRAS, NRAS, HRAS L3MBTL1 2380/4885ALDH1A1 2427/4885TAAR1 3554/4885
US-20090215899-A9 N-Phenyloxamide derivatives SERPINE1, SERPINH1, F12 L3MBTL1 1734/4885ALDH1A1 397/4885TAAR1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.